SSTR4

SSTR4 (somatostatin receptor subtype 4) is a member of the somatostatin receptor family and belongs to the class A G protein-coupled receptor (GPCR) superfamily with seven transmembrane domains, mediating cellular responses to somatostatin signaling.^[1][2] Mechanistically, SSTR4 regulates intracellular signaling through inhibition of adenylate cyclase activity and activation of downstream kinase pathways, including phosphoinositide-3 kinase (PI3K) and extracellular signal-regulated kinase (ERK)/MAPK signaling, thereby linking receptor activation to neuronal and cellular responses.^[3][4] Consistent with its prominent expression in the central nervous system, SSTR4 has been implicated in the regulation of neuronal excitability, and receptor activation couples to the M-current to modulate seizure susceptibility in experimental models.^[5] Disease-related studies further demonstrate that selective SSTR4 activation produces analgesic effects in preclinical pain models, where the highly selective agonist J-2156 reverses pain-like behaviors and reduces spinal ERK phosphorylation associated with central sensitization.^[6] Compared with other somatostatin receptor isoforms, SSTR4 has attracted particular interest because it mediates analgesic, anti-inflammatory, and antidepressant actions without the endocrine effects commonly associated with other receptor subtypes, supporting efforts to achieve subtype-selective pharmacology.^[7] For experimental applications, selective agonists including J-2156 and other SSTR4-preferring ligands are widely used to investigate receptor-specific signaling, neurobiology, and therapeutic mechanisms while minimizing off-target activation of related somatostatin receptor isoforms.^[6][7]